DBV Technologies Shares Soar After Positive Phase 3 Clinical Trial Results
DBV Technologies' stock closed the session on Wednesday, December 17, with a significant increase, reaching 3.68 euros from 3.07 euros the previous day. This rise followed the announcement on Tuesday evening of positive preliminary results from the phase 3 VITESSE clinical trial of the Viaskin Peanut patch, intended to treat children aged 4 to 7 years with peanut allergies. The trial met its primary efficacy endpoint with a difference of 31.8 percentage points between the treated group and the placebo, far exceeding the 15% threshold required by the FDA. This news triggered a surge in trading volumes and a series of target price upgrades by analysts, reflecting a renewed confidence from investors after years of regulatory uncertainties.
Outstanding Clinical Trial Results
The VITESSE clinical trial enabled 46.6% of treated children to respond favorably after 12 months, compared to 14.8% under placebo, with a 95% confidence interval ranging from 24.5 to 39.0%, significantly exceeding FDA expectations. This announcement comes amid a strong acceleration in the stock over several time horizons: the weekly performance reached 27.12%, while gains are at 130.1% over three months and 493.4% over a year. Today's trading represented 3.79% of the circulating capital, indicating a marked interest from investors in this news. At the Paris Stock Exchange, DBV's stock increased by 30% on Wednesday, December 17, in the late morning, bringing its rise to 530% for the entirety of 2025. The stock is now trading at 3.75 euros, well above its 50-day moving average of 2.61 euros, confirming a structurally bullish trend. The technical support at 2.26 euros provides a comfortable safety net, while the resistance at 3.45 euros was breached following the announcement.
Technical Indicators Show Strong Momentum
Technically, the Relative Strength Index (RSI) stands at 68, indicating a moderately overbought zone where buying pressures dominate but have not yet reached extreme levels that might prompt an immediate reversal. This level reflects sustained bullish momentum, fueled by the favorable clinical news. The MACD, a momentum indicator, shows a clearly bullish setup with a line at 0.19 and a signal at 0.10, generating a positive histogram of 0.09. This divergence between the line and the signal confirms that buying flows are gradually strengthening, reflecting an active accumulation dynamic. The monthly volatility remains high at 28.43%, characteristic of biotechnological stocks where movements can be abrupt depending on regulatory or clinical announcements. With a beta of 0.50, DBV Technologies shows moderate sensitivity to general market fluctuations, partly explaining its outperformance compared to a relatively stable CAC 40 over the same periods.
Anticipating Regulatory Approval and Market Entry
The company plans to file a Biologics License Application with the FDA in the first half of 2026, a crucial step for the commercialization of the Viaskin Peanut patch in the United States. The FDA has granted the Viaskin Peanut patch Breakthrough Therapy designation, and the company expects that the application may be eligible for priority review. This prospect prompted several analysts to revise their price targets upwards as early as this Wednesday on the American listing: Guggenheim raised its target price from 35 to 51 dollars while maintaining a buy recommendation, and Cantor Fitzgerald increased its target from 42 to 48 dollars with an overweight recommendation. In Paris, Kempen also raised its target from 6.50 to 11 euros while maintaining a buy advice. Portzamparc believes that Viaskin Peanut now has a good chance of receiving regulatory approval given its risk profile and fewer side effects, and has upgraded its advice from hold to strengthen. These adjustments reflect a renewed confidence in the commercial prospects of the product after multiple regulatory setbacks since 2020.
